Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao'er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxia… Read more
Market Cap & Net Worth: Yipinhong Pharmaceutical Co Ltd Class A (300723)
Yipinhong Pharmaceutical Co Ltd Class A (SHE:300723) has a market capitalization of $2.02 Billion (CN¥14.82 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #8880 globally and #1744 in its home market, demonstrating a 2.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yipinhong Pharmaceutical Co Ltd Class A's stock price CN¥32.82 by its total outstanding shares 451692766 (451.69 Million).
Yipinhong Pharmaceutical Co Ltd Class A Market Cap History: 2017 to 2026
Yipinhong Pharmaceutical Co Ltd Class A's market capitalization history from 2017 to 2026. Data shows growth from $785.74 Million to $2.02 Billion (17.21% CAGR).
Yipinhong Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.72x
Yipinhong Pharmaceutical Co Ltd Class A's market cap is 0.72 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $785.74 Million | $1.38 Billion | $156.70 Million | 0.57x | 5.01x |
| 2018 | $586.39 Million | $1.43 Billion | $208.22 Million | 0.41x | 2.82x |
| 2019 | $846.53 Million | $1.64 Billion | $143.69 Million | 0.52x | 5.89x |
| 2020 | $891.19 Million | $1.68 Billion | $225.61 Million | 0.53x | 3.95x |
| 2021 | $1.44 Billion | $2.20 Billion | $306.92 Million | 0.65x | 4.69x |
| 2022 | $1.40 Billion | $2.28 Billion | $290.68 Million | 0.61x | 4.81x |
| 2023 | $1.82 Billion | $2.50 Billion | $184.61 Million | 0.73x | 9.85x |
| 2024 | $1.05 Billion | $1.45 Billion | -$540.04 Million | 0.72x | N/A |
Competitor Companies of 300723 by Market Capitalization
Companies near Yipinhong Pharmaceutical Co Ltd Class A in the global market cap rankings as of March 18, 2026.
Key companies related to Yipinhong Pharmaceutical Co Ltd Class A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Yipinhong Pharmaceutical Co Ltd Class A Historical Marketcap From 2017 to 2026
Between 2017 and today, Yipinhong Pharmaceutical Co Ltd Class A's market cap moved from $785.74 Million to $ 2.02 Billion, with a yearly change of 17.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.02 Billion | -2.18% |
| 2025 | CN¥2.07 Billion | +96.66% |
| 2024 | CN¥1.05 Billion | -42.27% |
| 2023 | CN¥1.82 Billion | +30.21% |
| 2022 | CN¥1.40 Billion | -3.00% |
| 2021 | CN¥1.44 Billion | +61.63% |
| 2020 | CN¥891.19 Million | +5.28% |
| 2019 | CN¥846.53 Million | +44.36% |
| 2018 | CN¥586.39 Million | -25.37% |
| 2017 | CN¥785.74 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Yipinhong Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.02 Billion USD |
| MoneyControl | $2.02 Billion USD |
| MarketWatch | $2.02 Billion USD |
| marketcap.company | $2.02 Billion USD |
| Reuters | $2.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.